flurbiprofen Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory agents, ibuprofen derivatives | 1219 | 5104-49-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
| 0.20 | g | R |
| 44 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 2.90 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 17.55 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 92 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 31, 1986 | FDA | ALLERGAN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Angioedema | 107.80 | 20.88 | 45 | 1830 | 39297 | 46644890 |
| Toxic anterior segment syndrome | 94.70 | 20.88 | 21 | 1854 | 2116 | 46682071 |
| Allergy test positive | 76.45 | 20.88 | 13 | 1862 | 321 | 46683866 |
| Drug reaction with eosinophilia and systemic symptoms | 55.61 | 20.88 | 26 | 1849 | 29522 | 46654665 |
| Pancreatitis acute | 44.06 | 20.88 | 21 | 1854 | 24851 | 46659336 |
| Urticaria | 37.99 | 20.88 | 34 | 1841 | 117858 | 46566329 |
| Eosinophilic myocarditis | 36.06 | 20.88 | 7 | 1868 | 366 | 46683821 |
| Eyelid oedema | 32.21 | 20.88 | 13 | 1862 | 10344 | 46673843 |
| Symptom recurrence | 29.62 | 20.88 | 6 | 1869 | 390 | 46683797 |
| Altered state of consciousness | 27.58 | 20.88 | 15 | 1860 | 23333 | 46660854 |
| Lip oedema | 24.80 | 20.88 | 8 | 1867 | 3356 | 46680831 |
| Acute kidney injury | 21.73 | 20.88 | 36 | 1839 | 235819 | 46448368 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic anterior segment syndrome | 34.19 | 24.70 | 8 | 808 | 1513 | 29950149 |
| Hypertrophic cardiomyopathy | 32.38 | 24.70 | 7 | 809 | 926 | 29950736 |
| Abnormal dreams | 28.40 | 24.70 | 10 | 806 | 8105 | 29943557 |
| Ischaemic cerebral infarction | 26.86 | 24.70 | 6 | 810 | 923 | 29950739 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AE09 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Propionic acid derivatives |
| ATC | M02AA19 | MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use |
| ATC | R02AX01 | RESPIRATORY SYSTEM THROAT PREPARATIONS THROAT PREPARATIONS Other throat preparations |
| ATC | S01BC04 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids |
| FDA CS | M0001335 | Anti-Inflammatory Agents, Non-Steroidal |
| FDA MoA | N0000000160 | Cyclooxygenase Inhibitors |
| FDA EPC | N0000175722 | Nonsteroidal Anti-inflammatory Drug |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drugs |
| CHEBI has role | CHEBI:35493 | anti-pyretic |
| CHEBI has role | CHEBI:35544 | cyclooxygenase inhibitors |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D016861 | Cyclooxygenase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
| Osteoarthritis | indication | 396275006 | |
| Prevention of Ocular Surgery-Induced Miosis | indication | ||
| Dysmenorrhea | off-label use | 266599000 | |
| Alcoholism | contraindication | 7200002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Body fluid retention | contraindication | 43498006 | |
| Chronic heart failure | contraindication | 48447003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Gastrointestinal perforation | contraindication | 51875005 | |
| Acute nephropathy | contraindication | 58574008 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Coronary artery bypass graft | contraindication | 232717009 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Impaired wound healing | contraindication | 271618001 | |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Ocular Bleeding | contraindication |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.2 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | IC50 | 8.74 | WOMBAT-PK | CHEMBL | |||
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 8.39 | WOMBAT-PK | CHEMBL | |||
| Fatty acid-binding protein, intestinal | Cytosolic other | Ki | 4.59 | CHEMBL | |||||
| Aldo-keto reductase family 1 member C3 | Enzyme | IC50 | 5.81 | CHEMBL | |||||
| Aldo-keto reductase family 1 member C2 | Enzyme | IC50 | 4.49 | CHEMBL | |||||
| Fatty acid-binding protein, liver | Unclassified | Ki | 5.93 | CHEMBL | |||||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 6.77 | CHEMBL | |||||
| Prostaglandin G/H synthase 1 | Enzyme | Ki | 6 | CHEMBL | |||||
| Prostaglandin G/H synthase 2 | Enzyme | IC50 | 6.30 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019154 | VUID |
| N0000147399 | NUI |
| D00330 | KEGG_DRUG |
| 4019153 | VANDF |
| 4019154 | VANDF |
| C0016377 | UMLSCUI |
| CHEBI:42446 | CHEBI |
| FLP | PDB_CHEM_ID |
| 3394 | PUBCHEM_CID |
| CHEMBL563 | ChEMBL_ID |
| CHEMBL1200990 | ChEMBL_ID |
| CHEMBL3989754 | ChEMBL_ID |
| DB00712 | DRUGBANK_ID |
| D005480 | MESH_DESCRIPTOR_UI |
| 4194 | IUPHAR_LIGAND_ID |
| 3220 | INN_ID |
| 5GRO578KLP | UNII |
| 4502 | RXNORM |
| 4753 | MMSL |
| 4754 | MMSL |
| 72 | MMSL |
| d00239 | MMSL |
| 002382 | NDDF |
| 003968 | NDDF |
| 11633008 | SNOMEDCT_US |
| 373506008 | SNOMEDCT_US |
| 54344006 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Flurbiprofen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0711 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| FLURBIPROFEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-096 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 11 sections |
| Flurbiprofen Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-615 | SOLUTION/ DROPS | 0.24 mg | OPHTHALMIC | ANDA | 20 sections |
| Flurbiprofen Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-314 | SOLUTION/ DROPS | 0.30 mg | OPHTHALMIC | ANDA | 20 sections |
| FLURBIPROFEN SODIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-023 | SOLUTION/ DROPS | 0.30 mg | OPHTHALMIC | NDA authorized generic | 18 sections |
| Flurbiprofen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-992 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
| Flurbiprofen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-918 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
| Flurbiprofen Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3946 | SOLUTION/ DROPS | 0.30 mg | OPHTHALMIC | ANDA | 20 sections |
| Flurbiprofen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3362 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
| Flurbiprofen Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63187-937 | SOLUTION/ DROPS | 0.30 mg | OPHTHALMIC | ANDA | 20 sections |
| Flurbiprofen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8338 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
| Flurbiprofen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-4436 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
| Flurbiprofen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68788-7341 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Flurbiprofen Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69292-722 | SOLUTION/ DROPS | 0.30 mg | OPHTHALMIC | ANDA | 20 sections |
| Antiphlamine Pain Relieving | HUMAN OTC DRUG LABEL | 1 | 69642-1300 | PATCH | 33 mg | TOPICAL | unapproved drug other | 8 sections |